Bibliografías temáticas / Hydergine / Artículos de revistas

Artículos de revistas sobre el tema "Hydergine"

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Hydergine.
Autor: Grafiati
Publicado: 26 de julio de 2024
Última modificación: 28 de julio de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Hydergine".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Nussenblatt, RobertB, HowardA Austin, AlanG Palestine y HarryG Preuss. "HYDERGINE AND CYCLOSPORIN NEPHROTOXICITY". Lancet 327, n.º 8491 (mayo de 1986): 1220–21. http://dx.doi.org/10.1016/s0140-6736(86)91209-2.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

TAMURA, TAKASHI, TAIICHI SATOH, HISANORI MINAKAMI y TARO TAMADA. "Effect of Hydergine in Hyperprolactinemia". Journal of Clinical Endocrinology & Metabolism 69, n.º 2 (agosto de 1989): 470–74. http://dx.doi.org/10.1210/jcem-69-2-470.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Guida, Charles V. "Review: Hydergine is effective for dementia". ACP Journal Club 122, n.º 1 (1 de enero de 1995): 17. http://dx.doi.org/10.7326/acpjc-1995-122-1-017.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Kho, T. L., R. Kengen, K. M. L. Leunissen, J. Teule y J. P. Van Hooff. "HYDERGINE AND REVERSIBILITY OF CYCLOSPORIN NEPHROTOXICITY". Lancet 328, n.º 8503 (agosto de 1986): 394–95. http://dx.doi.org/10.1016/s0140-6736(86)90077-2.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

&NA;. "Hydergine-LC appears ineffective in Alzheimer's disease". Inpharma Weekly &NA;, n.º 751 (agosto de 1990): 9–10. http://dx.doi.org/10.2165/00128413-199007510-00027.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Romero, R., A. Felip, J. M. Llibre, J. Bonet y A. Caralps. "Co-Dergocrine Mesylate (Hydergine) and Hypertensive Emergencies". Nephron 51, n.º 1 (1989): 127–28. http://dx.doi.org/10.1159/000185270.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Schneider, L. S. y J. T. Olin. "Overview of Clinical Trials of Hydergine in Dementia". Archives of Neurology 51, n.º 8 (1 de agosto de 1994): 787–98. http://dx.doi.org/10.1001/archneur.1994.00540200063018.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Kuskowski, Michael A., Gerald Morley, Stephen M. Malone, Maurice W. Dysken y Amy Okaya. "Hydergine Treatment and Psychophysiological Measures in Primary Degenerative Dementia". Journal of Geriatric Psychiatry and Neurology 3, n.º 1 (enero de 1990): 41–47. http://dx.doi.org/10.1177/089198879000300109.

Texto completo
Resumen
Changes in smooth pursuit eye movements and the P300 component of the auditory evoked potential were studied in patients with primary degenerative dementia during a double-blind, placebo-controlled study of ergoloid mesylates (Hydergine). After 18 weeks of treatment, P300 latency and amplitude, recorded at three scalp electrode sites, had not changed significantly. Smooth pursuit gain was elevated for the drug group under some stimulus conditions, suggesting a normalization of pursuit eye movement functioning. However, the results of several other measures of the quality of pursuit eye movements failed to corroborate this finding. ( J Geriatr Psychiatry Neurol 1990; 3:41-47).
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Sobky, A. El, M. El Shazly, A. K. Darwish, T. Davies, K. Griffin y M. S. Keshavan. "Hydergine effect on prolactin and reaction time in dementia". Biological Psychiatry 21, n.º 12 (octubre de 1986): 1229–30. http://dx.doi.org/10.1016/0006-3223(86)90230-1.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Lon, S., M. D. Schneider, T. Jason y A. M. Olin. "Meta-analysis of hydergine clinical trials in primary dementia". Neurobiology of Aging 13 (enero de 1992): S123. http://dx.doi.org/10.1016/0197-4580(92)90613-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

TAKEHARA, KAZUHIKO. "Clinical usefulness of hydergine tablets for Raynaud phenomenon in scleroderma." Nishi Nihon Hifuka 58, n.º 5 (1996): 840–42. http://dx.doi.org/10.2336/nishinihonhifu.58.840.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

BECHGAARD, POUL y LEIF PAULSEN. "Dihydrogenated Ergot Alkaloids (Hydergine) in the Treatment of Essential Hypertension." Acta Medica Scandinavica 145, n.º 3 (24 de abril de 2009): 189–99. http://dx.doi.org/10.1111/j.0954-6820.1953.tb07010.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Rodriguez, D. V., D. F. Peeler, R. R. Smith, T. S. Sanders y J. B. Beckett. "ATTENUATION OF ISCHEMIA-REPERFUSION INJURY IN GERBIL HIPPOCAMPUS BY HYDERGINE". Southern Medical Journal 84, Supplement (septiembre de 1991): 42. http://dx.doi.org/10.1097/00007611-199109001-00143.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Datta, Kapal D., Richard C. Evenson, Patrick J. Gannon y Earl P. Dick. "Efficacy of oral hydergine (ergoloid mesylates) in alcohol related encephalopathy". Progress in Neuro-Psychopharmacology and Biological Psychiatry 11, n.º 1 (enero de 1987): 87–90. http://dx.doi.org/10.1016/0278-5846(87)90035-2.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Thompson, Troy L., Christopher M. Filley, Wayne D. Mitchell, Kathleen M. Culig, Mary LoVerde y Richard L. Byyny. "Lack of Efficacy of Hydergine in Patients with Alzheimer's Disease". New England Journal of Medicine 323, n.º 7 (16 de agosto de 1990): 445–48. http://dx.doi.org/10.1056/nejm199008163230704.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Harirî, N., B. Falakal y O. Algan. "THE EFFECTS OF HYDERGINE ON THE SYNAPTIC PLASTICITY OF AGED RATS". Clinical Neuropharmacology 15 (1992): 560B. http://dx.doi.org/10.1097/00002826-199202001-01093.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Qizilbash, Nawab. "The Cochrane Dementia and Cognitive Impairment Group". Reviews in Clinical Gerontology 7, n.º 2 (febrero de 1997): 183–88. http://dx.doi.org/10.1017/s0959259897000208.

Texto completo
Resumen
Over 2000 randomized trials are reported in the literature for the treatment of dementia and cognitive decline. Yet the responses to the question, ‘Which treatments are effective in dementia?’ are likely to be various and conflicting. Wide variation in practice exists, and for drug therapy, where information is more readily available, different treatments are used in different countries. For example, only one drug (Hydergine) is licensed in the UK for dementia, though rarely used, while there are over 30 drugs in use in Japan for dementia and cognitive decline, five in Spain, and two in the USA. This inconsistency is likely to be even greater for interventions of psychological and behavioural therapies, environmental therapy and the organization of care.
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

PÖLDRE, ARVO. "Two-Year Results of Hydergine Therapy in Hypertension and Other Circulatory Disturbances". Acta Medica Scandinavica 155, n.º 6 (24 de abril de 2009): 437–48. http://dx.doi.org/10.1111/j.0954-6820.1956.tb14392.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

ROTHLIN, E., A. CERLETTI y H. EMMENEGGER. "Experimental Psycho-neurogenic Hypertension and its Treatment with Hydrogenated Ergot Alkaloids (Hydergine)". Acta Medica Scandinavica 154, S312 (24 de abril de 2009): 27–35. http://dx.doi.org/10.1111/j.0954-6820.1956.tb16947.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Sunderland, T., K. T. Putnam, R. Martinez, A. Mellow, B. A. Lawlor, B. Vitiello, S. Molchan, R. M. Cohen y H. Weingartner. "COGNITIVE EFFECTS OF LONG-TERM DEPRENYL AND HYDERGINE IN ALZHEIMERʼS DISEASE PATIENTS". Clinical Neuropharmacology 15 (1992): 161B. http://dx.doi.org/10.1097/00002826-199202001-00310.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

lmperato, Assunta, Maria Carmen Obinu, Laura Dazzi, Giovanna Carta, Maria Stefania Mascia, Maria Antonietta Casu y Gian Luigi Gessa. "Co-dergocrine (Hydergine) regulates striatal and hippocampal acetylcholine release through D2 receptors". NeuroReport 5, n.º 6 (febrero de 1994): 674–76. http://dx.doi.org/10.1097/00001756-199402000-00003.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Kitaoku, Yoshiyuki, Takashi Matsunaga y Hiroyuki Kitamura. "Clinical Study of Ternelin Therapy and Ternelin and Hydergine Therapy for Tinnitus." Practica Oto-Rhino-Laryngologica 88, n.º 5 (1995): 645–56. http://dx.doi.org/10.5631/jibirin.88.645.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Ehrly, A. M. y K. Saeger-Lorenz. "The effect of Hydergine® on the filterability of erythrocytes from hyperosmolar blood". Clinical Hemorheology and Microcirculation 12, n.º 2 (1992): 223–28. http://dx.doi.org/10.3233/ch-1992-12207.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

SINGH, S. K., J. N. M. IJZERMANS, R. L. MARQUET, R. W. F. DE BRUIN, D. L. WESTBROEK y J. JEEKEL. "EFFECT OF HYDERGINE ON CYCLOSPORINE-INDUCED NEPHROTOXICITY IN A RAT KIDNEY TRANSPLANTATION MODEL". Transplantation 43, n.º 4 (abril de 1987): 593–94. http://dx.doi.org/10.1097/00007890-198704000-00033.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

KAPPERT, ARNOLD, CARL-HENRIK SKOGLUND, ANDERS BERGHOLTZ y GUSTAV NYLIN. "The Effect of Hydergine (CCK) on Reflex Vasoconstriction and Reflex Blood Pressure Stimulation". Acta Medica Scandinavica 141, n.º 6 (24 de abril de 2009): 440–50. http://dx.doi.org/10.1111/j.0954-6820.1952.tb14234.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

Werneke, Ursula, Trevor Turner y Stefan Priebe. "Complementary medicines in psychiatry". British Journal of Psychiatry 188, n.º 2 (febrero de 2006): 109–21. http://dx.doi.org/10.1192/bjp.188.2.109.

Texto completo
Resumen
BackgroundThe use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed.AimsTo review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions.MethodElectronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines.ResultsPotentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and sadenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction.ConclusionsSystematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

Izumiyama, K. y K. Kogure. "Effect of dihydroergotoxine mesylate (Hydergine®) on delayed neuronal death in the gerbil hippocampus". Acta Neurologica Scandinavica 78, n.º 3 (septiembre de 1988): 214–20. http://dx.doi.org/10.1111/j.1600-0404.1988.tb03649.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

Huber, F., S. Köberle, H. Prestele y R. Spiegel. "Effects of long-term ergoloid mesylates (‘Hydergine’) administration in healthy pensioners: 5-year results". Current Medical Research and Opinion 10, n.º 4 (enero de 1986): 256–79. http://dx.doi.org/10.1185/03007998609110447.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

Amenta, Daniela, Fabio Ferrante, Flavio Franch y Francesco Amenta. "Effects of Long-Term Hydergine® Administration on Lipofuscin Accumulation in Senescent Rat Brain". Gerontology 34, n.º 5-6 (1988): 250–56. http://dx.doi.org/10.1159/000212963.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

Steurer, G., P. Fitscha, K. Ettl y H. Sinzinger. "Effects of hydergine on platelet deposition on “active” human carotid artery lesions and platelet function". Thrombosis Research 55, n.º 5 (septiembre de 1989): 577–89. http://dx.doi.org/10.1016/0049-3848(89)90390-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

Boulat, O., P. Waldmeier y L. Maitre. "3,4-Dihydroxyphenylacetic acid (DOPAC) as an index of noradrenaline turnover: Effects of hydergine� and vincamine". Journal of Neural Transmission 82, n.º 3 (octubre de 1990): 181–95. http://dx.doi.org/10.1007/bf01272761.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

Hariri, N. I., A. Büyüköztürk, L. Kanit, B. Ersöz y G. Menteş. "The effects of hydergine on the MAO activity of the aged and adult rat brain". European Neuropsychopharmacology 4, n.º 3 (septiembre de 1994): 399–400. http://dx.doi.org/10.1016/0924-977x(94)90231-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

Büyüköztürk, As'lihan, Lütfiye Kanıt, Biltan Ersöz, Gülriz Menteş y Nuran İ. Hariri. "The effects of hydergine on the MAO activity of the aged and adult rat brain". European Neuropsychopharmacology 5, n.º 4 (diciembre de 1995): 527–29. http://dx.doi.org/10.1016/0924-977x(95)80014-s.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

NAGASAWA, HARUO, KYUYA KOGURE, KOICHIRO KAWASHIMA, TATSUO IDO, MASATOSHI ITOH y JUN HATAZAWA. "Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography." Tohoku Journal of Experimental Medicine 162, n.º 3 (1990): 225–33. http://dx.doi.org/10.1620/tjem.162.225.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

Ammon, Ronald, Rehka Sharma, Steven R. Gambert y Krishan Lal Gupta. "Hydergine revisited: A statistical analysis of studies showing efficacy in the treatment of cognitively impaired elderly". AGE 18, n.º 1 (enero de 1995): 5–9. http://dx.doi.org/10.1007/bf02434076.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

Bullock, R. "Review: hydergine leads to greater global improvement and greater improvement on comprehensive rating scales in dementia". Evidence-Based Mental Health 2, n.º 1 (1 de febrero de 1999): 15. http://dx.doi.org/10.1136/ebmh.2.1.15.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

Shoptaw, Steven, Donnie W. Watson, Chris Reiber, Richard A. Rawson, Margaret A. Montgomery, Maria D. Majewska y Walter Ling. "Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST)". Addiction 100 (marzo de 2005): 78–90. http://dx.doi.org/10.1111/j.1360-0443.2005.00991.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

Orma, H. y S. Vannas. "OBSERVATIONS ON THE USE OF PH 203 AND HYDERGINE IN SOME CIRCULATORY DISTURBANCES OF THE FUNDUS AND VASCULAR RETINOPATHY". Acta Ophthalmologica 36, n.º 4 (27 de mayo de 2009): 734–49. http://dx.doi.org/10.1111/j.1755-3768.1958.tb02284.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

Meier-Ruge, W. "Effects of prolonged co-dergocrine mesylate (Hydergine®) treatment on local cerebral glucose uptake in aged Fischer 344 rats". Archives of Gerontology and Geriatrics 5, n.º 1 (abril de 1986): 65–77. http://dx.doi.org/10.1016/0167-4943(86)90009-9.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

Bertoni-Freddari, C., C. Giuli, C. Pieri, D. Paci, L. Amadio, M. Ermini y A. Dravid. "The Effect of Chronic Hydergine Treatment on the Plasticity of Synaptic Junctions in the Dentate Gyms of Aged Rats". Journal of Gerontology 42, n.º 5 (1 de septiembre de 1987): 482–86. http://dx.doi.org/10.1093/geronj/42.5.482.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

Rouy, L. M., A. M. Douillon, R. Compan y Y. Wolmark. "Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: A 6-month double-blind, placebo-controlled trial". Current Medical Research and Opinion 11, n.º 6 (enero de 1989): 380–89. http://dx.doi.org/10.1185/03007998909110139.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

Serino, Anthony, Kwai Kan, Kimberly Graves, Christopher Kule y Adam Anthony. "Age, strain, and semi-chronic hydergine treatment effects on motor activity and neuronal nucleic acid-protein metabolism in male mice". Life Sciences 67, n.º 12 (agosto de 2000): 1489–505. http://dx.doi.org/10.1016/s0024-3205(00)00732-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

Hochberg, Ingrid. "MORPHOLOGICAL STUDIES ON THE EFFECT OF HYDERGINE ON THE ANTERIOR HORN CELLS AND THE CELLS OF NUCLEI VII, X, AND XII". Acta Pathologica Microbiologica Scandinavica 32, n.º 2 (18 de agosto de 2009): 300–315. http://dx.doi.org/10.1111/j.1699-0463.1953.tb00255.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

Schoups, A. A., V. K. Saxena, K. Tombeur y W. P. De Potter. "Facilitation of the release of noradrenaline and neuropeptide Y by the α2-adrenoceptor blocking agents idazoxan and hydergine in the dog spleen". Life Sciences 42, n.º 5 (enero de 1988): 517–23. http://dx.doi.org/10.1016/0024-3205(88)90092-6.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

Amenta, Francesco, Anne-Lise Jaton y Alberto Ricci. "Effect of long term hydergine treatment on the age-dependent loss of mossy fibers and of granule cells in the rat hippocampus". Archives of Gerontology and Geriatrics 10, n.º 3 (mayo de 1990): 287–96. http://dx.doi.org/10.1016/0167-4943(90)90030-a.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

Saletu, B., J. Grünberger, P. Anderer, L. Linzmayer, G. Pakesch y G. Zyhlarz. "Effect-kinetics on brain protection of two codergocrine-mesylate preparations (Aramexe retard® and Hydergine®) by EEG mapping and psychometry under hypoxia". Archives of Gerontology and Geriatrics 18, n.º 2 (marzo de 1994): 81–99. http://dx.doi.org/10.1016/0167-4943(94)00533-8.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

Arrigo, A., R. Casale, I. Giorgi, C. Guarnaschelli y F. Zelaschi. "Effects of Intravenous High Dose Co-Dergocrine Mesylate (‘Hydergine’®) in Elderly Patients with Severe Multi-Infarct Dementia: a Double-Blind, Placebo-Controlled Trial". Current Medical Research and Opinion 11, n.º 8 (enero de 1989): 491–500. http://dx.doi.org/10.1185/03007998909110460.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

Unseld, H. "Vasospasmus nach Leberruptur, Dopamin- und Hydergin®-Infusion". AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie 20, n.º 06 (diciembre de 1985): 339–41. http://dx.doi.org/10.1055/s-2007-1003135.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Gripwall, E. y A. Pöldre. "Einige Erfahrungen aus der Behandlung von essentieller Hypertonie mit Hydergin". Acta Medica Scandinavica 154, S312 (24 de abril de 2009): 245–47. http://dx.doi.org/10.1111/j.0954-6820.1956.tb16991.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

Thienhaus, Ole J., Beverly G. Wheeler, Sandra Simon, Frank P. Zemlan y James T. Hartford. "A Controlled Double-Blind Study of High-Dose Dihydroergotoxine Mesylate (HydergineR) in Mild Dementia". Journal of the American Geriatrics Society 35, n.º 3 (marzo de 1987): 219–23. http://dx.doi.org/10.1111/j.1532-5415.1987.tb02312.x.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía